Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

KOBE UNIVERSITY

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: Private

Established: 1949-01-01

Employees: 1K

Market Cap: -

Website: http://www.kobe-u.ac.jp

Clinical Trials

A Extension Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance ( EMPIRE-02 )

Phase 3

Conditions: Lipoatrophic Diabetes Mellitus
Insulin Resistance Syndrome
Insulin Resistance - Type A
Insulin Resistance - Type B

Interventions: Drug: Empagliflozin Tablets

First Posted Date: 2020-01-09

Last Posted Date: 2021-06-03

Lead Sponsor: Kobe University

Target Recruit Count: 8

Registration Number: NCT04221152

Locations: 🇯🇵
Kobe University Hospital, Kobe, Hyogo, Japan
🇯🇵
Tohoku University Hospita, Sendai, Miyagi, Japan
🇯🇵
Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan

and more 2 locations

A Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance

Phase 3

Conditions: Insulin Resistance - Type B
Insulin Resistance Syndrome
Insulin Resistance - Type A
Lipoatrophic Diabetes Mellitus

Interventions: Drug: Empagliflozin Tablets

First Posted Date: 2019-07-12

Last Posted Date: 2021-03-03

Lead Sponsor: Kobe University

Target Recruit Count: 8

Registration Number: NCT04018365

Locations: 🇯🇵
Kobe University Hospital, Kobe, Hyogo, Japan
🇯🇵
Tohoku University Hospital, Sendai, Miyagi, Japan
🇯🇵
Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan

and more 2 locations

Evaluation of Fractional Flow Reserve Calculated by Computed Tomography Coronary Angiography in Patients Undergoing TAVR

Not Applicable

Conditions: Coronary Artery Disease
Aortic Valve Stenosis

Interventions: Device: iFR / FFR measurement

First Posted Date: 2018-09-11

Last Posted Date: 2018-09-13

Lead Sponsor: Kobe University

Target Recruit Count: 25

Registration Number: NCT03665389

Lesional Evaluation of High Risk Patients With Neoatherosclerosis Treated With Rosuvastatin and Eicosapentaenoic Acid Using Optical Coherence Tomography(OCT)[LINK IT TWO]

Phase 4

Conditions: Coronary Artery Disease
Angina Pectoris

Interventions: Drug: EPA and rosuvastatin
Drug: High dose rosuvastatin

First Posted Date: 2018-09-05

Last Posted Date: 2018-09-18

Lead Sponsor: Kobe University

Target Recruit Count: 75

Registration Number: NCT03657758

Locations: 🇯🇵
Kobe University Graduate School of Medicine, Department of Cardiology, Kobe, Hyogo, Japan

The Efficacy of Alirocumab for Thin-cap fIbroatheroma in Patients With Coronary Artery Disease Estimated by Optical Coherence Tomography

Phase 4

Conditions: Coronary Artery Disease
Thin-cap fIbroatheroma

Interventions: Drug: Alirocumab

First Posted Date: 2018-06-11

Last Posted Date: 2018-11-14

Lead Sponsor: Kobe University

Target Recruit Count: 24

Registration Number: NCT03552432

Locations: 🇯🇵
Kobe University Graduate School of Medicine, Department of Cardiology, Kobe, Hyogo, Japan

Relation Among HDL Functionality, Neoatherosclerosis and Target Lesion Revascularization

Completed

Conditions: Coronary Artery Disease Progression

Interventions: Other: neoatherosclerosis

First Posted Date: 2018-05-30

Last Posted Date: 2018-05-30

Lead Sponsor: Kobe University

Target Recruit Count: 181

Registration Number: NCT03540381

Locations: 🇯🇵
Kobe University Graduate School of Medicine, Department of Cardiology, Kobe, Hyogo, Japan

To Evaluate the Efficacy of Alirocumab for Neoatherosclerosis by Using OCT, in Comparison With Standard Statin Therapy

Recruiting

Conditions: Coronary Artery Disease Progression

Interventions: Drug: Alirocumab

First Posted Date: 2018-05-23

Last Posted Date: 2018-05-30

Lead Sponsor: Kobe University

Target Recruit Count: 31

Registration Number: NCT03533959

Locations: 🇯🇵
Kobe University Graduate School of Medicine, Department of Cardiology, Kobe, Hyogo, Japan

Effect of Alirocumab(Proprotein Convertase Subtilisin/Kexin type9 Inhibitor) and Rosuvastatin or Rosuvastatin Alone on Lipid Core Plaques in Coronary Artery Disease Evaluated by Near-infrared Spectroscopy Intravascular Ultrasound

Phase 4

Conditions: Angina Pectoris
Coronary Artery Disease

Interventions: Drug: Alirocumab 75 MG/ML [Praluent]+ Rosuvastatin 10mg/daily
Drug: Rosuvastatin calcium10mg

First Posted Date: 2018-05-18

Last Posted Date: 2018-08-31

Lead Sponsor: Kobe University

Target Recruit Count: 30

Registration Number: NCT03529253

Locations: 🇯🇵
Kobe University Graduate School of Medicine, Department of Cardiology, Kobe, Hyogo, Japan

Effect of Rosuvastatin and Eicosapentaenoic Acid on Neoatherosclerosis: The LINK-IT Trial

Phase 4

Completed

Conditions: Coronary Artery Disease Progression

Interventions: Drug: Standard dose rosuvastatin
Drug: EPA and high dose rosuvastatin

First Posted Date: 2017-06-20

Last Posted Date: 2018-01-09

Lead Sponsor: Kobe University

Target Recruit Count: 50

Registration Number: NCT03192579

Comparisons of Morphological Measurement Between Coronary Computed Tomography and Optical Coherence Tomography

Completed

Conditions: Coronary Artery Disease

Interventions: Other: data collection, non-intervention

First Posted Date: 2017-01-13

Last Posted Date: 2017-01-13

Lead Sponsor: Kobe University

Target Recruit Count: 72

Registration Number: NCT03021382

Locations: 🇯🇵
Kobe University Graduate School of Medicine, Department of Cardiology, Kobe, Hyogo, Japan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy